Formuepleje A S Takes Position in IDEXX Laboratories, Inc. $IDXX

Formuepleje A S purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,855 shares of the company’s stock, valued at approximately $977,000.

A number of other hedge funds have also added to or reduced their stakes in the company. SHP Wealth Management bought a new stake in IDEXX Laboratories during the fourth quarter worth $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth $25,000. Elevation Wealth Partners LLC raised its holdings in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after buying an additional 32 shares in the last quarter. Finally, Wormser Freres Gestion lifted its position in shares of IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock worth $37,000 after buying an additional 47 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Citigroup boosted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Barclays dropped their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. UBS Group lifted their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $747.00.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $535.38 on Monday. IDEXX Laboratories, Inc. has a twelve month low of $518.55 and a twelve month high of $769.98. The stock’s fifty day simple moving average is $558.27 and its 200 day simple moving average is $570.05. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $42.18 billion, a P/E ratio of 37.65, a P/E/G ratio of 2.86 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period last year, the company earned $3.50 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.